Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 6

Treatment of grass pollen allergy: focus on a standardized grass allergen extract – Grazax®

Authors Calderón M, Brandt T

Published 5 December 2008 Volume 2008:4(6) Pages 1255—1260


Review by Single-blind

Peer reviewer comments 2

Moisés Calderón1, Tove Brandt2

1Section of Allergy and Clinical Immunology, Royal Brompton Hospital, Imperial College, NHLI, London, UK; 2Group Clinical Development, ALK-Abelló A/S, Hørsholm, Denmark

Abstract: Immunotherapy is the only treatment for allergy that has the potential to alter the natural course of the disease. Sublingual immunotherapy (SLIT) for grass pollen-induced rhino-conjunctivitis has been developed to make immunotherapy available to a broader group of allergic patients. In the largest clinical programme ever conducted with allergen-specific immunotherapy, over 1,700 adults and 260 children have been exposed to Grazax®. Grazax is formulated as an oral lyophilisate (tablet) for sublingual administration, containing 75,000 SQ-T standardized allergen extract of grass pollen from Phleum pratense. Grazax is indicated for treatment of grass pollen-induced rhinitis and conjunctivitis in adult patients with clinically relevant symptoms and diagnosed with a positive skin prick test and/or specific IgE test to grass pollen. In phase I trials doses from 2,500 to 1,000,000 SQ-T were tested. All doses were well tolerated and 75,000 SQ-T, with approximately 15 µg major allergen protein, was chosen as the optimal dose. Three phase III trials are ongoing, one being a long-term trial. Results from GT-08 trial first and second treatment years showed a reduction of 30% and 36%, respectively, in daily rhino-conjunctivitis symptom scores and a reduction of 38% and 46% of daily rhinoconjunctivitis medication scores compared with placebo over the entire grass pollen season. Subjects treated with Grazax also had an increased number of well days and improved quality of life, and more subjects experienced excellent rhino-conjunctivitis control. The most common adverse events related to Grazax are local reactions, such as pruritus, edema mouth, ear pruritus, throat irritation, and sneezing. We conclude that Grazax is efficacious and safe for treatment of rhino-conjunctivitis due to grass pollen allergy.

Keywords: sublingual immonotherapy, grass pollen allergy, rhinoconjunctivitis, immunotherapy, tablet

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups

Assaad-Khalil SH, Najem R, Sison J, Kitchlew AR, Cho BL, Ueng KC, DiTommaso S, Shete A

Vascular Health and Risk Management 2015, 11:71-78

Published Date: 21 January 2015

Nanoformulated cell-penetrating survivin mutant and its dual actions

Sriramoju B, Kanwar RK, Kanwar JR

International Journal of Nanomedicine 2014, 9:3279-3298

Published Date: 10 July 2014

Adjunctive treatment with oral AKL1, a botanical nutraceutical, in chronic obstructive pulmonary disease

Brockwell C, Ampikaipakan S, Sexton DW, Price D, Freeman D, Thomas M, Ali M, Wilson AM

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:715-721

Published Date: 9 July 2014

Highly biocompatible, nanocrystalline hydroxyapatite synthesized in a solvothermal process driven by high energy density microwave radiation

Smolen D, Chudoba T, Malka I, Kedzierska A, Lojkowski W, Swieszkowski W, Kurzydlowski KJ, Kolodziejczyk-Mierzynska M, Lewandowska-Szumiel M

International Journal of Nanomedicine 2013, 8:653-668

Published Date: 12 February 2013

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]

Tsumura T, Yoshikawa K, Suzumura H, Kimura T, Sasaki S, Kimura I, Takeda R

Clinical Ophthalmology 2013, 7:129-130

Published Date: 16 January 2013

RGD-tagged helical rosette nanotubes aggravate acute lipopolysaccharide-induced lung inflammation

Suri SS, Mills S, Aulakh GK, Rakotondradany F, Fenniri H, Singh B

International Journal of Nanomedicine 2011, 6:3113-3123

Published Date: 2 December 2011

In vitro and in vivo effects of polyethylene glycol (PEG)-modified lipid in DOTAP/cholesterol-mediated gene transfection

Torben Gjetting, Nicolai Skovbjerg Arildsen, Camilla Laulund, et al

International Journal of Nanomedicine 2010, 5:371-383

Published Date: 25 May 2010